Impact cardiovasculaire des incrétino-mimétiques chez le diabétique de type 2 : le point en 2015

Incretinomimetics (GLP-1 receptor agonists and DPP-4 inhibitors) are nowadays an important therapeutic approach in patients with type 2 diabetes (T2D). In view of the increased risk of cardiovascular morbimortality in T2D, it is essential for clinicians to evaluate the safety of these new drugs in this field. The aim of this paper is to review, on the basis of recent scientific literature, cardiovascular effects of GLP-1 receptor agonists and DPP-4 inhibitors. Up to now, experimental and clinical studies suggest rather a cardiovascular safety of these drugs. However, long term well designed studies should confirm this particular aspect and in particular precise if DPP-4 inhibitors are associated or not with an increased risk of congestive heart failure.